secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001558370-23-012631
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics announces $645M ex-US BRIUMVI deal with Neuraxpharm; Q2 net sales $16M
--------------------------------------------------------------------------------

- Upfront cash payment $140M plus $12.5M at first European launch; total deal up to $645M with milestones and double-digit royalties up to 30%.
- Q2 2023 BRIUMVI net sales $16M (100% QoQ growth); cumulative net product revenue $23.8M since U.S. launch in January 2023.
- Over 1,200 prescriptions from 340+ providers at 225+ centers; payor coverage for ~80% of covered lives.
- Pro-forma cash including upfront ~$285M; Q2 net loss $47.6M vs $40.5M in prior-year quarter.
- TG retains option to buy back ex-U.S. rights for ~2 years in event of a change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/0001558370-23-012631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837023012631/tgtx-20230728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer